EUVIMEDEUVIMED entdecken
Crossref

Long-term follow-up of growth and puberty in 3-M syndrome: effects of growth hormone therapy and response variability

Ayse Pinar Ozturk, Ayca Dilruba Aslanger, Umut Altunoglu, Cagri Gulec, Esin Karakilic Ozturan, Volkan Karaman, Elif Yilmaz Gulec, Alper Gezdirici, Gozde Yesil, Guven Toksoy, Melek Yildiz, Sukran Poyrazoglu und 4 weitere

Endocrine · 2025

DOI: 10.1007/s12020-025-04417-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine, 2025. Verfasst von Ayse Pinar Ozturk und 15 weiteren Autor:innen. Beteiligte Einrichtung: Istanbul University, Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul, Turkey. ozturk.aysep@gmail.com. Hauptthemen laut MEDLINE: Human Growth Hormone, Puberty, Dwarfism, Muscle Hypotonia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: 3-M syndrome is a rare autosomal recessive growth disorder characterised by severe prenatal and postnatal growth retardation, resulting from mutations in the CUL7, OBSL1, or CCDC8 genes. This study aimed to assess the effects of recombinant human growth hormone (rhGH) therapy in individuals with 3-M syndrome. METHODS: A retrospective analysis was conducted on 24 patients (19 males and 5 females) from 16 unrelated families, all with clinically and genetically confirmed diagnoses of 3-M syndrome. Growth patterns and pubertal development were evaluated. RESULTS: The median age of the patients was 6.8 years (0.5–21.2). Thirteen families were consanguineous. Median birth weight SDS was −3.8 (−6.3 to −1.4), with all patients born small for gestational age (SGA), except for one patient. All individuals presented with marked growth retardation, with a median height SDS of −4.1 (−7.9 to −2.7). Dysmorphic features characteristic of 3-M syndrome and delayed bone age were observed in all patients. Genetic testing identified pathogenic or likely pathogenic variants in CUL7 in 4 families (25%) and in OBSL1 in the remaining 75%. The rhGH therapy was initiated in 13 patients, with a median starting age of 7.5 years (2.4–13.1) and treatment duration ranging from 1 to 7 years. The overall median change in height SDS was +0.3 (–0.8 to +2.3), reflecting variability in response among patients receiving treatment. A favorable response was observed in 7 out of 13 patients (54%). Pubertal arrest was noted in seven male patients, while two female siblings and one male patient experienced rapidly progressive puberty. CONCLUSION: 3-M syndrome should be included in the differential diagnosis of individuals presenting with severe prenatal and postnatal growth retardation. The rhGH therapy may offer benefit in some cases, although response is variable. Pubertal arrest can occur in males with 3-M syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormonePubertyDwarfismMuscle HypotoniaSpineHumansFemaleMaleChildRetrospective StudiesFollow-Up StudiesAdolescentChild, PreschoolInfantYoung AdultCullin ProteinsBody HeightTreatment OutcomeCytoskeletal Proteins

Stichwörter der Autor:innen

3-M syndromePubertyRecombinant human growth hormone treatmentSGAShort stature

Substanzen

Human Growth HormoneCUL7 protein, humanCullin ProteinsOBSL1 protein, humanCytoskeletal Proteins

Autor:innen und Institutionen

  • Istanbul University, Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul, Turkey. ozturk.aysep@gmail.com.
  • Istanbul University, Istanbul Faculty of Medicine, Department of Medical Genetics, Istanbul, Turkey.
  • Koc University School of Medicine, Medical Genetics Department, Istanbul, Turkey.
  • Istanbul University, Istanbul Faculty of Medicine, Department of Pediatrics, Pediatric Endocrinology Unit, Istanbul, Turkey.
  • Medeniyet University, Medical Genetics Department, Istanbul, Turkey.
  • Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Medical Genetics Department, Istanbul, Turkey.

Zitieren

APA

Ozturk, A. P., Aslanger, A. D., Altunoglu, U., Gulec, C., Karakilic Ozturan, E., Karaman, V., Yilmaz Gulec, E., Gezdirici, A., Yesil, G., Toksoy, G., Yildiz, M., Poyrazoglu, S., Bas, F., Uyguner, Z. O., Kayserili, H., & Darendeliler, F. (2025). Long-term follow-up of growth and puberty in 3-M syndrome: effects of growth hormone therapy and response variability. Endocrine. https://doi.org/10.1007/s12020-025-04417-2

Vancouver

Ozturk AP, Aslanger AD, Altunoglu U, Gulec C, Karakilic Ozturan E, Karaman V, et al. Long-term follow-up of growth and puberty in 3-M syndrome: effects of growth hormone therapy and response variability. Endocrine. 2025. doi:10.1007/s12020-025-04417-2

BibTeX
@article{Ozturk2025,
  author = {Ozturk, Ayse Pinar and Aslanger, Ayca Dilruba and Altunoglu, Umut and Gulec, Cagri and Karakilic Ozturan, Esin and Karaman, Volkan and Yilmaz Gulec, Elif and Gezdirici, Alper and Yesil, Gozde and Toksoy, Guven and Yildiz, Melek and Poyrazoglu, Sukran and Bas, Firdevs and Uyguner, Zehra Oya and Kayserili, Hulya and Darendeliler, Feyza},
  title = {Long-term follow-up of growth and puberty in 3-M syndrome: effects of growth hormone therapy and response variability},
  journal = {Endocrine},
  year = {2025},
  doi = {10.1007/s12020-025-04417-2}
}
Kostenlos starten →